Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

"Keep on ROCKIn": Repurposed ROCK inhibitors to boost corneal endothelial regeneration

H. Vercammen, M. Ondra, J. Kotulova, EC. De La Hoz, C. Witters, K. Jecmenova, M. Le Compte, C. Deben, S. Ní Dhubhghaill, C. Koppen, M. Hajdúch, B. Van den Bogerd

. 2024 ; 174 (-) : 116435. [pub] 20240320

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014109

The global shortage of corneal endothelial graft tissue necessitates the exploration of alternative therapeutic strategies. Rho-associated protein kinase inhibitors (ROCKi), recognized for their regenerative potential in cardiology, oncology, and neurology, have shown promise in corneal endothelial regeneration. This study investigates the repurposing potential of additional ROCKi compounds. Through screening a self-assembled library of ROCKi on B4G12 corneal endothelial cells, we evaluated their dose-dependent effects on proliferation, migration, and toxicity using live-cell imaging. Nine ROCKi candidates significantly enhanced B4G12 proliferation compared to the basal growth rate. These candidates were further assessed for their potential to accelerate wound closure as another indicator for tissue regeneration capacity, with most demonstrating notable efficacy. To assess the potential impact of candidate ROCKi on key corneal endothelial cell markers related to cell proliferation, leaky tight junctions and ion efflux capacity, we analyzed the protein expression of cyclin E1, CDK2, p16, ZO-1 and Na+/K+-ATPase, respectively. Immunocytochemistry and western blot analysis confirmed the preservation of corneal endothelial markers post-treatment with ROCKi hits. However, notable cytoplasm enlargement and nuclear fragmentation were detected after the treatment with SR-3677 and Thiazovivin, indicating possible cellular stress. In compared parameters, Chroman-1 at a concentration of 10 nM outperformed other ROCKi, requiring significantly 1000-fold lower effective concentration than established ROCKi Y-27632 and Fasudil. Altogether, this study underscores the potential of repurposing ROCKi for treating corneal endothelial dysfunctions, offering a viable alternative to conventional grafting methods, and highlights Chroman-1 as a promising candidate structure for hit-to-lead development.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014109
003      
CZ-PrNML
005      
20240905133815.0
007      
ta
008      
240725e20240320fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.biopha.2024.116435 $2 doi
035    __
$a (PubMed)38513591
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Vercammen, Hendrik $u Antwerp Research Group for Ocular Science (ARGOS), Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium; Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium; DrugVision Lab, University of Antwerp, Wilrijk, Belgium. Electronic address: hendrik.vercammen@uantwerpen.be
245    10
$a "Keep on ROCKIn": Repurposed ROCK inhibitors to boost corneal endothelial regeneration / $c H. Vercammen, M. Ondra, J. Kotulova, EC. De La Hoz, C. Witters, K. Jecmenova, M. Le Compte, C. Deben, S. Ní Dhubhghaill, C. Koppen, M. Hajdúch, B. Van den Bogerd
520    9_
$a The global shortage of corneal endothelial graft tissue necessitates the exploration of alternative therapeutic strategies. Rho-associated protein kinase inhibitors (ROCKi), recognized for their regenerative potential in cardiology, oncology, and neurology, have shown promise in corneal endothelial regeneration. This study investigates the repurposing potential of additional ROCKi compounds. Through screening a self-assembled library of ROCKi on B4G12 corneal endothelial cells, we evaluated their dose-dependent effects on proliferation, migration, and toxicity using live-cell imaging. Nine ROCKi candidates significantly enhanced B4G12 proliferation compared to the basal growth rate. These candidates were further assessed for their potential to accelerate wound closure as another indicator for tissue regeneration capacity, with most demonstrating notable efficacy. To assess the potential impact of candidate ROCKi on key corneal endothelial cell markers related to cell proliferation, leaky tight junctions and ion efflux capacity, we analyzed the protein expression of cyclin E1, CDK2, p16, ZO-1 and Na+/K+-ATPase, respectively. Immunocytochemistry and western blot analysis confirmed the preservation of corneal endothelial markers post-treatment with ROCKi hits. However, notable cytoplasm enlargement and nuclear fragmentation were detected after the treatment with SR-3677 and Thiazovivin, indicating possible cellular stress. In compared parameters, Chroman-1 at a concentration of 10 nM outperformed other ROCKi, requiring significantly 1000-fold lower effective concentration than established ROCKi Y-27632 and Fasudil. Altogether, this study underscores the potential of repurposing ROCKi for treating corneal endothelial dysfunctions, offering a viable alternative to conventional grafting methods, and highlights Chroman-1 as a promising candidate structure for hit-to-lead development.
650    12
$a kinázy asociované s rho $x antagonisté a inhibitory $x metabolismus $7 D054460
650    12
$a proliferace buněk $x účinky léků $7 D049109
650    12
$a inhibitory proteinkinas $x farmakologie $7 D047428
650    12
$a rohovkový endotel $x účinky léků $7 D004728
650    12
$a regenerace $x účinky léků $7 D012038
650    _2
$a zvířata $7 D000818
650    _2
$a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
650    _2
$a pohyb buněk $x účinky léků $7 D002465
650    _2
$a buněčné linie $7 D002460
650    _2
$a lidé $7 D006801
650    _2
$a endoteliální buňky $x účinky léků $7 D042783
655    _2
$a časopisecké články $7 D016428
700    1_
$a Ondra, Martin $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic; Czech Advanced Technology and Research Institute (CATRIN), Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Kotulova, Jana $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a De La Hoz, Edgar Cardenas $u Industrial Vision Lab, University of Antwerp, Wilrijk, Belgium
700    1_
$a Witters, Charissa $u Antwerp Research Group for Ocular Science (ARGOS), Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium; Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium; DrugVision Lab, University of Antwerp, Wilrijk, Belgium
700    1_
$a Jecmenova, Katerina $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Le Compte, Maxim $u DrugVision Lab, University of Antwerp, Wilrijk, Belgium
700    1_
$a Deben, Christophe $u DrugVision Lab, University of Antwerp, Wilrijk, Belgium
700    1_
$a Ní Dhubhghaill, Sorcha $u Department of Ophthalmology, Brussels University Hospital, Jette, Belgium
700    1_
$a Koppen, Carina $u Antwerp Research Group for Ocular Science (ARGOS), Translational Neurosciences, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium; Department of Ophthalmology, Antwerp University Hospital, Edegem, Belgium
700    1_
$a Hajdúch, Marián $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic; Czech Advanced Technology and Research Institute (CATRIN), Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Van den Bogerd, Bert $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic; Czech Advanced Technology and Research Institute (CATRIN), Palacky University Olomouc, Olomouc, Czech Republic. Electronic address: Bert.VandenBogerd@uantwerpen.be
773    0_
$w MED00005486 $t Biomedicine & pharmacotherapy $x 1950-6007 $g Roč. 174 (20240320), s. 116435
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38513591 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905133809 $b ABA008
999    __
$a ok $b bmc $g 2143718 $s 1225975
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 174 $c - $d 116435 $e 20240320 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace